Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B
- PMID: 23102120
- PMCID: PMC3532743
- DOI: 10.1016/j.jalz.2011.09.229
Imaging brain amyloid in nondemented young adults with Down syndrome using Pittsburgh compound B
Abstract
Down syndrome (DS) is one of the most common causes of intellectual disability. Although DS accounts for only 15% of all individuals with intellectual disabilities, adults with DS account for approximately 60% of individuals with intellectual disabilities and Alzheimer's disease. This is thought to be because of overproduction of the β-amyloid (Aβ) protein due to trisomy for the Aβ precursor protein gene on chromosome 21. Pittsburgh compound B (PiB) is a noninvasive in vivo positron emission tomography tracer used to image amyloid deposition in living humans. Studies using PiB have shown an age-dependent asymptomatic amyloid deposition in more than 20% of the cognitively normal elderly population. Presymptomatic carriers of presenilin (PS-1) and Aβ precursor protein gene mutations who are destined to develop Alzheimer's disease also show preclinical amyloid deposition. This report describes a pilot study involving the use of PiB in seven adults with DS (age: 20-44 years). Compared with objective cutoffs for amyloid positivity in older non-DS cognitively normal control subjects, only two of the seven DS subjects (age: 38 and 44 years) showed increased PiB retention. The remaining five subjects aged between 20 and 35 years showed no detectable increase in PiB retention. Interestingly, the two subjects who showed elevated PiB retention showed a striatal-predominant pattern similar to that previously reported for PS-1 mutation carriers. These results demonstrate the feasibility of conducting PiB positron emission tomography scanning in this special population, and suggest a link between Aβ overproduction and early striatal deposition of fibrillar Aβ.
Copyright © 2012 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.
Figures
Similar articles
-
Using positron emission tomography and Carbon 11-labeled Pittsburgh Compound B to image Brain Fibrillar β-amyloid in adults with down syndrome: safety, acceptability, and feasibility.Arch Neurol. 2011 Jul;68(7):890-6. doi: 10.1001/archneurol.2011.36. Epub 2011 Mar 14. Arch Neurol. 2011. PMID: 21403005
-
The effects of normal aging on amyloid-β deposition in nondemented adults with Down syndrome as imaged by carbon 11-labeled Pittsburgh compound B.Alzheimers Dement. 2016 Apr;12(4):380-90. doi: 10.1016/j.jalz.2015.05.013. Epub 2015 Jun 13. Alzheimers Dement. 2016. PMID: 26079411 Free PMC article.
-
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh Compound B units of brain Aβ amyloid.Alzheimers Dement. 2011 Mar;7(2):133-41. doi: 10.1016/j.jalz.2010.08.230. Epub 2011 Feb 1. Alzheimers Dement. 2011. PMID: 21282074 Free PMC article.
-
Relationship between memory performance and β-amyloid deposition at different stages of Alzheimer's disease.Neurodegener Dis. 2012;10(1-4):141-4. doi: 10.1159/000334295. Epub 2012 Feb 1. Neurodegener Dis. 2012. PMID: 22301812 Review.
-
A Review of Functional Neuroimaging in People with Down Syndrome with and without Dementia.Dement Geriatr Cogn Dis Extra. 2021 Dec 27;11(3):324-332. doi: 10.1159/000520880. eCollection 2021 Sep-Dec. Dement Geriatr Cogn Dis Extra. 2021. PMID: 35111192 Free PMC article. Review.
Cited by
-
Detection and treatment of Alzheimer's disease in its preclinical stage.Nat Aging. 2023 May;3(5):520-531. doi: 10.1038/s43587-023-00410-4. Epub 2023 May 18. Nat Aging. 2023. PMID: 37202518 Review.
-
Exploring the role of sex differences in Alzheimer's disease pathogenesis in Down syndrome.Front Neurosci. 2022 Aug 12;16:954999. doi: 10.3389/fnins.2022.954999. eCollection 2022. Front Neurosci. 2022. PMID: 36033603 Free PMC article. Review.
-
Rodent Modeling of Alzheimer's Disease in Down Syndrome: In vivo and ex vivo Approaches.Front Neurosci. 2022 Jun 7;16:909669. doi: 10.3389/fnins.2022.909669. eCollection 2022. Front Neurosci. 2022. PMID: 35747206 Free PMC article. Review.
-
Joint-label fusion brain atlases for dementia research in Down syndrome.Alzheimers Dement (Amst). 2022 May 25;14(1):e12324. doi: 10.1002/dad2.12324. eCollection 2022. Alzheimers Dement (Amst). 2022. PMID: 35634535 Free PMC article.
-
Psychosocial Risk Factors for Alzheimer's Disease in Patients with Down Syndrome and Their Association with Brain Changes: A Narrative Review.Neurol Ther. 2022 Sep;11(3):931-953. doi: 10.1007/s40120-022-00361-9. Epub 2022 May 21. Neurol Ther. 2022. PMID: 35596914 Free PMC article. Review.
References
-
- Hook EB, Cross PK, Schreinemachers DM. Chromosomal abnormality rates at amniocentesis and in live-born infants. JAMA. 1983;249:2034–8. - PubMed
-
- Zigman WB, Schupf N, Devenny DA, Miezejeski C, Ryan R, Urv TK, et al. Incidence and prevalence of dementia in elderly adults with mental retardation without Down syndrome. Am J Ment Retard. 2004;109:126–41. - PubMed
-
- Janicki MP, Dalton AJ. Prevalence of dementia and impact on intellectual disability services. Ment Retard. 2000;38:276–88. - PubMed
-
- Janicki MP, Dalton AJ, Henderson CM, Davidson PW. Mortality and morbidity among older adults with intellectual disability: health services considerations. Disabil Rehab. 1999;21:284–94. - PubMed
-
- Visser FE, Aldenkamp AP, van Huffelen AC, Kuilman M, Overweg J, van Wijk J. Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment Retard. 1997;101:400–12. - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
